UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 149

Sortiert nach

Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia

Journal of antimicrobial chemotherapy, 2016-09, Vol.71 (9), p.2646-2650

2016

Volltextzugriff (PDF)

Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat'AIDS cohort

PloS one, 2019-09, Vol.14 (9), p.e0222067-e0222067

2019

Volltextzugriff (PDF)

Impact of age-related comorbidities on five-year overall mortality among elderly HIV-infected patients in the late HAART era — Role of chronic renal disease

The Journal of nutrition, health & aging, 2016-04, Vol.20 (4), p.408-414

2016

Volltextzugriff (PDF)

Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations

Journal of antimicrobial chemotherapy, 2020-10, Vol.75 (10), p.2981-2985

2020

Volltextzugriff (PDF)

Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group

Annals of oncology, 2016-03, Vol.27 (3), p.397-408

2016

Volltextzugriff (PDF)

Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia

Journal of antimicrobial chemotherapy, 2018-02, Vol.73 (2), p.490-493

2018

Volltextzugriff (PDF)

Infectious complications in HIV-infected kidney transplant recipients

International journal of STD & AIDS, 2018-03, Vol.29 (4), p.341-349

2018

Volltextzugriff (PDF)

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens

Journal of antimicrobial chemotherapy, 2012-06, Vol.67 (6), p.1475-1478

2012

Volltextzugriff (PDF)

Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors

Infectious diseases now (Online), 2021-02, Vol.51 (1), p.90-93

2021

Volltextzugriff (PDF)

Low immune response rate of HIV-infected patients to a single injection of hepatitis A vaccine

Infectious diseases now (Online), 2021-02, Vol.51 (1), p.94-96

2021

Volltextzugriff (PDF)

Olfactory and gustatory dysfunctions in COVID-19 outpatients: A prospective cohort study

Infectious diseases now (Online), 2021-08, Vol.51 (5), p.440-444

2021

Volltextzugriff (PDF)

Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients

Journal of antimicrobial chemotherapy, 2010-03, Vol.65 (3), p.556-561

2010

Volltextzugriff (PDF)

Prevalence and factors associated with symptom persistence: A prospective study of 429 mild COVID-19 outpatients

Infectious diseases now (Online), 2022-03, Vol.52 (2), p.75-81

2022

Volltextzugriff (PDF)

HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients

Journal of clinical virology, 2015-12, Vol.73, p.32-35

2015

Volltextzugriff (PDF)

A large French prospective cohort of HIV‐infected patients: the Nadis Cohort

HIV medicine, 2009-09, Vol.10 (8), p.504-511

2009

Volltextzugriff (PDF)

Early Detection of Hepatitis C Virus Infection by Use of a New Combined Antigen-Antibody Detection Assay: Potential Use for High-Risk Individuals

Journal of Clinical Microbiology, 2006-04, Vol.44 (4), p.1561-1563

2006

Volltextzugriff (PDF)

Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART

Journal of antimicrobial chemotherapy, 2018-08, Vol.73 (8), p.2141-2146

2018

Volltextzugriff (PDF)

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study

Journal of antimicrobial chemotherapy, 2014-06, Vol.69 (6), p.1648-1652

2014

Volltextzugriff (PDF)

Long-term follow-up of HIV-infected patients on dolutegravir monotherapy

Journal of antimicrobial chemotherapy, 2020-03, Vol.75 (3), p.675-680

2020

Volltextzugriff (PDF)

Long COVID-19 symptoms: Clinical characteristics and recovery rate among non-severe outpatients over a six-month follow-up

Infectious diseases now (Online), 2022-05, Vol.52 (3), p.165-169

2022

Volltextzugriff (PDF)

Body fat distribution in HIV‐infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI‐ANRS136 Substudy

HIV medicine, 2012-09, Vol.13 (8), p.505-515

2012

Volltextzugriff (PDF)

Acute hepatitis C in HIV‐infected men who have sex with men

HIV medicine, 2004-07, Vol.5 (4), p.303-306

2004

Volltextzugriff (PDF)

Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA

AIDS (London), 2003-11, Vol.17 (17), p.2471-2477

2003

Volltextzugriff (PDF)

Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score

Infection, 2014-04, Vol.42 (2), p.295-301

2014

Volltextzugriff (PDF)

Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen

Journal of antimicrobial chemotherapy, 2021-01, Vol.76 (2), p.477-481

2021

Volltextzugriff (PDF)

1 – 25 von 149

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(134)

Publikationsform

Artikel
(146)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia

Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat'AIDS cohort

Impact of age-related comorbidities on five-year overall mortality among elderly HIV-infected patients in the late HAART era — Role of chronic renal disease

Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations

Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group

Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia

Infectious complications in HIV-infected kidney transplant recipients

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens

Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors

Low immune response rate of HIV-infected patients to a single injection of hepatitis A vaccine

Olfactory and gustatory dysfunctions in COVID-19 outpatients: A prospective cohort study

Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients

Prevalence and factors associated with symptom persistence: A prospective study of 429 mild COVID-19 outpatients

HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients

A large French prospective cohort of HIV‐infected patients: the Nadis Cohort

Early Detection of Hepatitis C Virus Infection by Use of a New Combined Antigen-Antibody Detection Assay: Potential Use for High-Risk Individuals

Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study

Long-term follow-up of HIV-infected patients on dolutegravir monotherapy

Long COVID-19 symptoms: Clinical characteristics and recovery rate among non-severe outpatients over a six-month follow-up

Body fat distribution in HIV‐infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI‐ANRS136 Substudy

Acute hepatitis C in HIV‐infected men who have sex with men

Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA

Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score

Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen

Suchergebnisse filtern